Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) Share Price Rises 8.9% Today

Oxygenta Pharmaceutical Ltd. traded at Rs 71.48, up 8.9% today, taking its market capitalisation to Rs 242.76 crore and placing the micro-cap pharma stock among today’s notable gainers.

Oxygenta Pharmaceutical Ltd. Share Price moved higher to Rs 71.48 on 12 August 2026, a gain of 8.9% from the previous close of Rs 65.64, lifting the company’s market capitalisation to Rs 242.76 crore. For traders tracking Stock Market Today and BSE market movers, the move stands out because the stock qualified on Univest’s price rise screen for its Micro Cap category.

Today’s move also puts Oxygenta Pharmaceutical Ltd. Share Price Today into the list of Stocks in News and Top Gainers Today within the smaller-cap healthcare space. The verified data confirms the price event, the intraday strength and the volume traded on BSE, although it does not establish a company-specific catalyst behind the move. That distinction matters because a strong one-day gain can reflect price action, liquidity shifts or broader interest in a stock without immediately proving a fresh operational trigger.

At the same time, the numbers offer useful context for investors searching for Oxygenta Pharmaceutical Ltd. Stock News, Oxygenta Pharmaceutical Ltd. Share News and Oxygenta Pharmaceutical Ltd. Share Price Update. The company operates in Healthcare, specifically Pharmaceuticals & Drugs, and its valuation and profitability profile are unusual: a negative P/E of -19.48, a negative P/B of -5.42, ROE of 0 and ROCE of 3.18. In this Univest stock analysis, the important next step is to separate the day’s momentum from the company’s underlying financial picture, sector positioning and peer comparison.

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 71.48
Previous Close	Rs 65.64
Today's Change	+Rs 5.84 (+8.9%)
Day Open	Rs 68.3
Day High	Rs 71.59
Day Low	Rs 68.3
Current Volume (BSE)	3,437
BSE Traded Volume	3,437
Combined NSE + BSE Volume	3,437
Turnover	Rs 0.02 crore
Market Capitalisation	Rs 242.76 crore
Market Cap Category	Micro Cap

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) traded at Rs 71.48. versus the previous close of Rs 65.64, a rise of 8.9%. The stock opened at Rs 68.3, reached Rs 71.59, touched Rs 68.3. Reported volume was 3,437.

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 242.76 crore
P/E Ratio	-19.48x
P/B Ratio	-5.42x
ROE	0%
ROCE	3.18%
EPS	Rs -3.67
Dividend Yield	0%

Oxygenta Pharmaceutical Ltd. was valued at a P/E ratio of -19.48x, a P/B ratio of -5.42x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 0% and ROCE of 3.18%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs -3.67, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Oxygenta Pharmaceutical Ltd. Fundamental Analysis shows a company that is drawing attention because of today’s share price gain, yet the underlying numbers remain mixed to weak on profitability and valuation interpretation. The company’s market capitalisation stands at Rs 242.76 crore, which places it above the industry median market cap of Rs 146.94 crore but below the industry average of Rs 484.32 crore within the same Pharmaceuticals & Drugs benchmark universe.

The valuation ratios require careful reading. Oxygenta Pharmaceutical Ltd. Share Price is associated with a P/E ratio of -19.48 and a P/B ratio of -5.42. Both negative values indicate that conventional valuation comparison is less straightforward than for consistently profitable peers with positive earnings and positive net worth. A negative EPS of -3.67 means earnings attributable to each share were negative on the supplied basis, which helps explain why the stock cannot be discussed through standard earnings-multiple logic in the same way as many industry peers. For investors searching Oxygenta Pharmaceutical Ltd. Financial Results or Oxygenta Pharmaceutical Ltd. Earnings context, that negative EPS is one of the most important authenticity checks in the data.

Profitability metrics also show limited strength. ROE is 0, while ROCE is 3.18. ROE at 0 suggests the business is not currently generating a return on shareholder equity in the supplied dataset, and ROCE of 3.18 is materially below stronger double-digit returns typically associated with efficient capital deployment. Dividend yield stands at 0, which means the current or historical payout relative to the present share price is nil in the supplied data rather than a support factor for the stock today.

Put together, Oxygenta Pharmaceutical Ltd. Stock Analysis points to a company whose current market interest is being driven by today’s price rise rather than by obviously strong profitability metrics. That does not invalidate the move, but it does frame it. On Univest, this is the kind of setup where investors usually compare the day’s momentum with sector benchmarks and listed peers before drawing broader conclusions.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	-19.48x
Benchmark Median P/E	24.45x
Benchmark Average P/E	79.31x
Benchmark P/E Range	3.31x to 3,374.81x
Company P/B Ratio	-5.42x
Benchmark Median P/B	1.82x
Company ROE	0%
Benchmark Median ROE	10.49%
Company ROCE	3.18%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 242.76 crore
Benchmark Median Market Cap	Rs 146.94 crore

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) has a P/E ratio of -19.48x, which is below the benchmark median of 24.45x, a difference of -179.67%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) has a ROE of 0%, which is below the benchmark median of 10.49%, a difference of -100%. Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) has a ROCE of 3.18%, which is below the benchmark median of 12.97%, a difference of -75.48%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Oxygenta Pharmaceutical Ltd. operates in Healthcare and specifically in the Pharmaceuticals & Drugs industry, so the most useful comparison is against the supplied same-industry benchmark. That benchmark covers 136 companies, giving a meaningful frame for judging whether today’s Oxygenta Pharmaceutical Ltd. Share Price move sits against strong or weak underlying relative fundamentals.

On valuation, the company’s P/E of -19.48 is far below the benchmark median P/E of 24.45 and the benchmark average P/E of 79.31. The industry P/E range is wide, from 3.31 to 3,374.81 across 104 companies with available P/E data, which shows how dispersed valuations are within Pharmaceuticals & Drugs. The company’s P/B of -5.42 also sits below the benchmark median P/B of 1.82 and average P/B of 2.46, within an industry range from -16.74 to 16.32 across 135 companies. Negative P/B values are not interpreted the same way as standard positive book-multiple comparisons, but they clearly place the stock outside the industry norm.

Profitability comparison is also subdued. Company ROE is 0 against an industry median of 10.49 and average of 8.1. Company ROCE is 3.18 against an industry median of 12.97 and average of 15.64. Those figures show that, based on the supplied benchmark, Oxygenta Pharmaceutical Ltd. is currently below industry central tendencies on return ratios. Market capitalisation offers a different picture: at Rs 242.76 crore, the company is above the benchmark median of Rs 146.94 crore, though still below the benchmark average of Rs 484.32 crore and far below the industry maximum of Rs 2,949.87 crore.

For readers following Oxygenta Pharmaceutical Ltd. Latest News, the sector view matters because it shows a healthcare stock posting a strong one-day gain despite return metrics that remain below industry medians. Univest therefore reads today’s move as market-relevant price action first, with sector benchmarking providing a useful but cautious financial backdrop.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,949.87	31.07	0.45	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,775.9	71.31	11.28	18.65	22.17
Hikal Ltd.	HIKAL	2,761.32	0	2.26	15.22	16.15
Sai Parenteral's Ltd.	SAIPARENT	2,594.65	179.52	3.32	13.9	12.97
Solara Active Pharma Sciences Ltd.	SOLARA	2,474.65	0	1.92	17.23	15.34

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) has a P/E ratio of -19.48x compared with the displayed peer median of 31.07x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 0% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 3.18% versus the displayed peer median of 15.34%, providing a capital-efficiency comparison. Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) has a market capitalisation of Rs 242.76 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Oxygenta Pharmaceutical Ltd. Share Price is best understood in relation to listed Pharmaceuticals & Drugs peers, especially because today’s move occurred in a space where valuation and profitability vary sharply from company to company. The supplied peer set includes Dishman Carbogen Amcis, Beta Drugs, Hikal, Sai Parenteral's, Solara Active Pharma Sciences, Panacea Biotec, NGL Fine-Chem, Hester Biosciences, Ind-Swift Laboratories and Indoco Remedies.

Against these peers, Oxygenta Pharmaceutical Ltd. remains much smaller on market cap at Rs 242.76 crore. Dishman Carbogen Amcis is at Rs 2,949.87 crore, Beta Drugs at Rs 2,775.9 crore, Hikal at Rs 2,761.32 crore, Sai Parenteral's at Rs 2,594.65 crore and Solara Active Pharma Sciences at Rs 2,474.65 crore. Even the lower end of the supplied peer range, such as Indoco Remedies at Rs 2,038.53 crore and Hester Biosciences at Rs 2,128.33 crore, is far above Oxygenta Pharmaceutical Ltd. Market Cap.

On valuation, peers with available P/E ratios are mostly positive and significantly higher: Dishman Carbogen Amcis at 31.07, Beta Drugs at 71.31, Sai Parenteral's at 179.52, NGL Fine-Chem at 44.41, Hester Biosciences at 15.51, Ind-Swift Laboratories at 43.16 and Indoco Remedies at 355.2. Oxygenta’s P/E of -19.48 therefore stands apart, signalling a very different earnings backdrop. The same applies to P/B. While peer P/B ratios range from 0.45 for Dishman Carbogen Amcis to 11.28 for Beta Drugs, Oxygenta’s -5.42 again highlights that direct premium-discount language is not very useful here.

Profitability is also lighter than most peers. Oxygenta’s ROCE of 3.18 is below Beta Drugs at 22.17, Hikal at 16.15, Sai Parenteral's at 12.97, Solara at 15.34, NGL Fine-Chem at 33.91, Hester Biosciences at 14.12 and Indoco Remedies at 15.67. ROE at 0 matches Panacea Biotec’s 0 but trails several peers with double-digit returns. For investors reading Oxygenta Pharmaceutical Ltd. Stock News, the peer view suggests that today’s BSE gain is a price event in a company whose comparative financial metrics remain less robust than many larger listed pharma names.

Why Investors Are Watching Oxygenta Pharmaceutical Ltd.

Investors are watching Oxygenta Pharmaceutical Ltd. because today’s market action combined a visible share price gain with micro-cap positioning in the Healthcare space. Oxygenta Pharmaceutical Ltd. Share Price Today rose 8.9% to Rs 71.48, and the stock traded close to its session high of Rs 71.59 after opening at Rs 68.3. That kind of move naturally pushes the company into intraday screens such as Top Gainers Today and Market Movers, especially when smaller-cap stocks start appearing in broader Share Market Today conversations.

• Verified price action: The stock rose Rs 5.84 from Rs 65.64 to Rs 71.48 in the same session.
• Intraday positioning: The day low equalled the open at Rs 68.3, while the day high reached Rs 71.59.
• Trading activity: Volume was 3,437 shares on BSE with turnover of Rs 0.02 crore.
• Fundamental backdrop: P/E was -19.48, P/B was -5.42, EPS was -3.67, ROE was 0 and ROCE was 3.18.
• Sector context: The company operates in Pharmaceuticals & Drugs, where benchmark median ROCE is 12.97 and median P/E is 24.45.

What investors may monitor next is whether Oxygenta Pharmaceutical Ltd. Share Price can sustain attention beyond a single-session move and how the stock is read against its industry benchmark and larger listed peers. Univest highlights this as a case where momentum is visible, but the supplied financial ratios still matter for context. That is why both price action and fundamental analysis should remain part of the same conversation.

About Oxygenta Pharmaceutical Ltd.

Oxygenta Pharmaceutical Ltd. is part of the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry. Based on the supplied company context, that places it in an industry where valuations, profitability and market capitalisation can vary widely across listed peers, from smaller micro-cap businesses to companies with market caps above Rs 2,000 crore.

In market terms, OXYGENTAPH is currently a micro-cap pharmaceutical stock with a market capitalisation of Rs 242.76 crore. Within the same-industry benchmark of 136 companies, that puts it above the median market cap of Rs 146.94 crore but well below the average of Rs 484.32 crore. This matters because company size affects liquidity, peer comparison and the way investors interpret a same-day price rise.

For readers looking for Oxygenta Pharmaceutical Ltd. NSE or Oxygenta Pharmaceutical Ltd. BSE references, the supplied trading data in this event is from BSE, where volume was 3,437 shares today. In practical stock analysis terms, Oxygenta Pharmaceutical Ltd. sits in a listed pharmaceutical universe where benchmark P/E, P/B, ROE and ROCE levels are mostly stronger than the company’s current supplied numbers, which makes today’s market move notable from a market update perspective.

Track Oxygenta Pharmaceutical Ltd. Share Price on Univest

Use Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Oxygenta Pharmaceutical Ltd. Share Price more closely can use Univest to track live share price movements, market capitalisation, 52-week levels, fundamental ratios and broader stock analysis. Univest also helps users place Oxygenta Pharmaceutical Ltd. Share Price Today in context by combining price action, sector data, peer comparison and company-level metrics in one view.

That is particularly useful for micro-cap stocks, where a single-session move can attract attention quickly but still needs to be read alongside valuation and profitability data. On Univest, users can monitor Oxygenta Pharmaceutical Ltd. Shareholding Pattern when available, follow market insights, compare pharmaceutical peers and review whether a one-day gain remains only a price event or becomes part of a larger stock performance trend.

Frequently Asked Questions

Why is Oxygenta Pharmaceutical Ltd. Share Price in focus today?

Ans. Oxygenta Pharmaceutical Ltd. Share Price is in focus because the stock rose 8.9% today to Rs 71.48 from the previous close of Rs 65.64. The move qualified under the price-rise event screen for its Micro Cap category.

What was Oxygenta Pharmaceutical Ltd. Share Price Today?

Ans. Oxygenta Pharmaceutical Ltd. Share Price Today was Rs 71.48 at the time of the event capture. The stock opened at Rs 68.3, touched a high of Rs 71.59 and a low of Rs 68.3 during the session.

How much did Oxygenta Pharmaceutical Ltd. stock rise today?

Ans. The stock rose by Rs 5.84 in absolute terms and 8.9% in percentage terms. It moved from the previous close of Rs 65.64 to Rs 71.48, making it one of the notable BSE gainers in today’s trade.

What is the market capitalisation of Oxygenta Pharmaceutical Ltd.?

Ans. Oxygenta Pharmaceutical Ltd. had a market capitalisation of Rs 242.76 crore in the supplied data. That places it in the Micro Cap category and above the same-industry median market cap of Rs 146.94 crore.

What does today’s volume show for Oxygenta Pharmaceutical Ltd.?

Ans. The stock traded 3,437 shares on BSE, with total volume also at 3,437 shares and turnover at Rs 0.02 crore. That confirms activity behind the price rise, though the absolute traded value remained modest.

Is Oxygenta Pharmaceutical Ltd. profitable based on the supplied figures?

Ans. The supplied figures show pressure on profitability. EPS was -3.67, P/E was -19.48 and ROE was 0, while ROCE stood at 3.18. These numbers indicate weaker earnings and return metrics than many industry peers.

How does Oxygenta Pharmaceutical Ltd. compare with its industry benchmark?

Ans. Within the 136-company Pharmaceuticals & Drugs benchmark, the company’s P/E of -19.48 was below the median 24.45 and average 79.31. ROCE of 3.18 was also below the industry median 12.97 and average 15.64.

What sector does Oxygenta Pharmaceutical Ltd. belong to?

Ans. Oxygenta Pharmaceutical Ltd. belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. That is relevant because today’s move should be assessed against sector valuation and return benchmarks, not only as a one-day stock price change.

How does Oxygenta Pharmaceutical Ltd. compare with listed pharma peers?

Ans. The company is much smaller than supplied peers such as Dishman Carbogen Amcis, Beta Drugs and Hikal, all above Rs 2,700 crore market cap. Its ROCE of 3.18 and negative P/E also differ from several peers’ stronger metrics.

What should investors monitor next in Oxygenta Pharmaceutical Ltd. Stock News?

Ans. Investors may monitor whether the stock holds above today’s key zone near Rs 68.3 to Rs 71.59, while also tracking valuation, EPS, ROE and ROCE context. On Univest, both price action and fundamentals remain important together.